Altria Group (MO) vs Regencell Bioscience (RGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 21, 2026.
Summary
Altria Group (MO) has outperformed Regencell Bioscience (RGC) over the past year, gaining 15.8% versus a loss of 32.6%. Over five years, RGC leads with a +2956.0% price change compared with +67.4% for MO. Altria Group is the larger company by market cap ($123.28 billion vs $5.36 billion), about 23.0 times the size.
Altria Group pays a dividend yielding 5.74%, while Regencell Bioscience does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MO | RGC |
|---|---|---|
| Share price | $73.83 | $10.80 |
| Market cap | $123.28B | $5.36B |
| 1-day change | -1.09% | +3.35% |
| YTD return | +28.04% | -48.57% |
| 1-year return | +15.81% | -32.63% |
| 5-year return | +67.38% | +2956.03% |
| P/E ratio (TTM) | 15.71 | — |
| Forward P/E | 12.59 | — |
| EPS (TTM) | $4.70 | $-0.03 |
| Dividend yield | 5.74% | 0.00% |
| Annual dividend | $4.24 | $0.00 |
| Revenue (latest FY) | $23.28B | — |
| Revenue growth (YoY) | -3.08% | — |
| Net income (latest FY) | $6.95B | $-11.70M |
| Gross margin | 62.47% | — |
| Operating margin | 42.52% | — |
| Net margin | 29.84% | — |
| 52-week high | $77.06 | $69.00 |
| 52-week low | $54.70 | $4.51 |
| Distance from 52-week high | -4.19% | -84.35% |
| Analyst consensus | hold | — |
| Avg. price target upside | -5.19% | — |
| Average volume | 8.62M | 237.88K |
| Shares outstanding | 1.67B | 495.88M |
| Employees | 5,900 | 10 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Altria Group is about 23.0 times larger than Regencell Bioscience by market value ($123.28B vs $5.36B).
- MO has outperformed RGC by 48.4 percentage points over the past year.
- Altria Group offers a meaningfully higher dividend yield (5.74% vs 0.00%).
About Altria Group
MO stock →Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. It offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and oral tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand.
Health Care · Medicinal Chemicals and Botanical Products · 5,900 employees
About Regencell Bioscience
RGC stock →Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 10 employees
MO vs RGC FAQ
Which is bigger, Altria Group or Regencell Bioscience?
Altria Group (MO) is larger, with a market capitalization of $123.28B compared with $5.36B for Regencell Bioscience (RGC).
Which stock has performed better over the past year, MO or RGC?
MO returned +15.81% over the past 12 months, compared with -32.63% for RGC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Altria Group or Regencell Bioscience?
Altria Group pays a dividend yielding 5.74%, while Regencell Bioscience does not currently pay a regular dividend.
Are Altria Group and Regencell Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.